Recent News

The latest news from the governments, medical industry and top online sources.

EMA establishes regular procedure for scientific advice on c…

EMA, in close collaboration with the European Commission, has established a standard procedure for manufacturers of certain high-risk medical devices to request scientific advice on their intended clinical development strategy and proposals for clinical investigation. Manufacturers of class III devices and class IIb active devices intended to administer or remove medicines can now submit their […]

Novartis secures MHRA authorisation for ribociclib

Breast cancer therapy offers hope for patients at risk of recurrence Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant treatment in combination with an aromatase inhibitor (AI) for patients with HR+/HER2- early breast cancer at high risk of recurrence. Previously, this treatment was only licensed for advanced […]

Two new vaccines against bluetongue recommended for approval

EMA has recommended the approval of the vaccines Bluevac-3 and Syvazul BTV 3 to protect sheep against bluetongue disease. Bluevac-3 is also approved for use in cattle. The disease is caused by the bluetongue virus, of which different types exist. These vaccines are shown to protect against the newly emerged serotype-3 bluetongue virus (BTV3), responsible […]

Pheno Therapeutics granted trial authorisation for MS candid…

First-in-human trial of PTD802 to commence following UK MHRA approval Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802. The small molecule therapeutic is designed to promote remyelination in neurological diseases, including multiple sclerosis (MS). PTD802 is a selective GPR17 antagonist developed under an exclusive worldwide […]

A common EU approach to data transparency in medicine regula…

EMA and HMA (Heads of Medicines Agencies) have published a comprehensive overhaul of their guidance on the identification of commercially confidential information (CCI) and personal data in marketing authorisation applications for human medicines. The update reaffirms the commitment of regulatory authorities across the European Economic Area (EEA) to extensive transparency when disclosing information, both in […]

MindMed begins phase 3 study of MM120 for anxiety disorder

First patient dosed in landmark trial for GAD treatment MindMed has announced the dosing of the first patient in its phase 3 Voyage study of MM120 ODT, a pharmaceutically optimised form of lysergide D-tartrate (LSD) for treating Generalised Anxiety Disorder (GAD). The study aims to evaluate the efficacy and safety of MM120 ODT compared to […]

Meeting highlights from the Committee for Veterinary Medicin…

CVMP opinions on veterinary medicinal products The Committee adopted by consensus a positive opinion for a marketing authorisation application for Icthiovac ERM from Laboratorios Hipra, S.A., a new vaccine for the active immunisation  of Atlantic salmon fry to reduce mortality caused by serotype O1 (biotypes 1 and 2) and serotype O2 (biotype 1) of Yersinia ruckeri in […]

KIMMTRAK recommended for funding by NICE for uveal melanoma …

Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute for Health and Care Excellence (NICE) and is now available through the NHS. This marks a significant reversal of last year’s negative decision, allowing the first treatment shown to prolong survival in HLA-A*02:01-positive adults with metastatic or unresectable […]

EMA encourages companies to submit type I variations for 202…

EMA is advising marketing authorisation holders to submit type IA and type IAINvariations for 2024 no later than 30 November 2024. This will enable EMA to acknowledge the validity of the submissions before the Agency’s closure between 20 December 2024 and 5 January 2025, within the 30-day timeframe set out in Article 14 of Commission Regulation (EC) […]

Lupin to develop near-zero global warming inhalers

Eco-friendly inhalers aim to reduce environmental impact Lupin Healthcare UK Ltd has announced plans to reformulate its pMDI inhalers with a near-zero global warming potential propellant as part of their commitment to achieving net-zero status by 2045. This development aligns with European and UK regulatory requirements and aims to reduce the environmental impact of inhalers […]